Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?

Arquivos de gastroenterologia - 1 Jan 2000

Andrade Vanessa Gutierrez de, Yamashiro Fabio da Silva, Oliveira Cassio Vieira, Kurozawa Leticia Lastória, Moreira Alecsandro, Silva Giovanni Faria

Abstract excerpt

BACKGROUND: The interaction between serum lipids and C virus infection is well known, as are serum lipid levels in the Peg-IFN / RBV-based treatment. However, with direct action antivirals (DAAs) this behavior is still unclear. OBJECTIVE: To compare serum lipids levels between patients treated with Peg-IFN/RBV and DAAs and to evaluate lipids in sustained virological response (SVR) with DAAs. METHODS: Retro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Lipids

Share to Polyethylene Glycols

Share to Ribavirin

Share to Sustained Virologic Response

Share to Triglycerides

Source

Identifiers

PMID: 30043871
DOI: 10.1590/S0004-2803.201800000-33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?PMID 30043871Read ↗

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity Read ↗

Effect of antiviral therapy for HCV on lipid levels.Semantic proximity Read ↗

Genotype specific peripheral lipid profile changes with hepatitis C therapy.Semantic proximity Read ↗

Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination.Semantic proximity Read ↗

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study.Semantic proximity Read ↗

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.Semantic proximity Read ↗

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.Semantic proximity Read ↗

[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].Semantic proximity Read ↗

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity Read ↗

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.Semantic proximity Read ↗

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.